The boards of Transcriptic and 3Scan have unanimously approved an agreement to merge companies to combine their considerable engineering capabilities in developing automated systems for chemistry, biology, and tissue analysis. The resulting new company is Strateos™. Transcriptic developed the first robotic cloud laboratory platform for on-demand life science research, which is currently in use at several top pharmaceutical and biotechnology companies. 3Scan combines automation, machine learning and computer vision to extract spatial data from tissue samples and create detailed 3D representations as well as quantitative analysis of complex anatomical structures. Now these two portfolios will be combined to offer a suite of technologies for accelerating drug discovery and early development. In support of the Strateos mission, DCVC (Data Collective) and Lux Capital have invested an additional $16.5M, including support from Dolby Family Ventures, to enable the combined company to expand.
StageBio has merged with Tox Path Specialists, LLC (TPS) to create the leading provider of research and preclinical histology, pathology, specialized neuropathology, and archiving services for the biopharmaceutical, medical device and contract research industries. StageBio was recently created by the merger of Histo Scientific Research Laboratories (HSRL) and Vet Path Services (VPS) and is a portfolio company of Ampersand Capital Partners. StageBio is the leading provider of GLP-compliant research and preclinical histology, pathology and specimen archiving services for the biopharmaceutical, medical device and contract research industries. Founded in 2006, TPS is one of the leading neuropathology laboratories in North America.
Masy BioServices today announced it has acquired Metrology Laboratories Inc. (MLI), a calibration services provider located in Rockaway, New Jersey. MLI will now be known as Masy BioServices. Masy BioServices, headquartered in Pepperell, Massachusetts, has provided reliable solutions to the life sciences community for over 35 years through an array of services including: calibration of primary standards and critical test equipment; validation and IQ/OQ/PQ of environmental chambers; autoclaves and thermal warehouse mapping; and lab equipment rental and sales.
Discovery Life Sciences’ (Discovery) announced today that it has entered into an agreement to add the Genomic Services Laboratory (GSL) of the HudsonAlpha Institute for Biotechnology, one of the world’s premier gene sequencing and bioinformatics laboratories, to form a new division: HudsonAlpha Discovery. The new division, in combination with Discovery’s current global biospecimen and analytic services, will provide the highest quality of clinically and scientifically annotated biospecimens, gene sequencing, bioinformatics, and laboratory services to the global pharmaceutical, biotechnology, and diagnostics industries. This agreement comes on the heels of Discovery’s recent European acquisitions and expansion which cemented the company’s position as the global leader in biospecimen analysis, procurement, processing, and distribution.
Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces it has completed the acquisition of Taueret Laboratories, LLC, a clinical and research molecular laboratory, for $9,747,800, with $1,200,000 paid at closing in the form of the Company’s restricted common stock and $8,547,800 to be paid on or before December 31, 2020, subject to certain conditions. Taueret Laboratories will join Predictive Technology Group’s newest subsidiary Predictive Laboratories. Taueret Laboratories is a privately held molecular laboratory focusing on human infertility, women’s health, and childhood diseases and performs genetic testing using state-of-the-art instrumentation.
Focused on advancing the next frontier of orthobiologics, IWEUS HEALTH announced Tuesday they have entered into a definitive agreement to acquire majority interest of Greyledge Technologies, LLC. IWEUS HEALTH is a privately held investment management company focused in the acquisition of cGXP laboratories and the development of healthcare capital projects. Greyledge is an FDA registered cellular therapy platform currently used in Orthopaedic and Cosmetic applications. This acquisition will accelerate the IWEUS HEALTH entry into translational healthcare with the potential for growth and expansion into other applications. Additionally, it allows IWEUS HEALTH the opportunity to provide physicians with a means to quantify orthobiologics for accurate clinical decisions and a means to document the product for patient records.
Harvard University and Deerfield Management, a healthcare investment firm, have established a major strategic R&D alliance to speed the development and translation of biomedical and life-science innovations into transformative treatments that can improve life, health, and medical care. Through a newly launched company called Lab1636, Deerfield has committed an unprecedented $100 million in initial funding to support the alliance. Spearheaded by Harvard Office of Technology Development (OTD), the alliance is expected to catalyze the development of novel therapeutics and rapidly drive innovations toward clinical validation. A private company wholly owned by affiliates of Deerfield, Lab1636 will support Harvard R&D projects throughout various stages of drug discovery and development, for example enabling studies to explicate the biology of disease, validate therapeutic targets, or achieve a proof-of-concept necessary for filing an Investigational New Drug (IND) application.
MolecularMD Corporation, a molecular diagnostic specialty laboratory that enables the development and commercialisation of precision medicines in oncology, announced today that it has been acquired by ICON plc (NASDAQ: ICLR). MolecularMD’s extensive scientific and clinical biomarker experience expands ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s laboratory service offering. MolecularMD’s specialty central laboratory offering and associated client base extends ICON’s reach into the support of precision medicine programs across all phases of drug ‘ diagnostic co-development.
Reaction Biology Corporation (www.reactionbiology.com) (“RBC”) and ChinaEquity Group (www.chinaequity.net) (“CEG”) announced Monday the completion of a stock swap transaction whereby RBC has acquired all the shares of ProQinase GmbH, an early stage drug-discovery company based in Freiburg, Germany. Founded in 2001, ProQinase specializes in kinase-based drug discovery, and in 2018 provided a full suite of biochemical and cell-based assays to over 230 customers worldwide. In addition, ProQinase has a large and growing offering of in vivo assay services, including 70 tumor models as well as immuno-oncology platforms with proprietary mouse models. Based in Malvern, Pennsylvania and formed in 2001, Reaction Biology is a leader in early stage drug-discovery services, with over 1,150 clients worldwide and a suite of 2000+ biochemical, cell-based, and biophysical assays.
Northlane Capital Partners is evaluating the sale of Science Care, a company that collects and distributes non-transplant body parts for medical research and surgeon training, according to four sources. Piper Jaffray has been engaged to offer sell-side financial advice on the sales process, the sources said.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.